文献速递肾癌与肾肿瘤

肾部分切除术中静脉甘露醇与安慰剂的随机双盲试验

Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial.
PubMed 文献 · Eur Urol · 2017-08-16

这项前瞻性随机双盲安慰剂对照试验纳入199例术前eGFR>45ml/min/1.73m2的肾部分切除术患者,比较术前30分钟内静脉给予甘露醇12.5g与安慰剂对术后6个月肾功能的影响。结果显示两组eGFR调整差异仅0.2单位,无统计学意义(p=0.9),95%CI上限排除临床相关效应,作者认为该常规做法不应继续。

要点

  • 肾部分切除术中静脉甘露醇12.5g与安慰剂相比,术后6个月eGFR无显著差异。
  • 调整后eGFR差异0.2单位(p=0.9),95%CI(-3.1至3.5)排除临床相关效应。
  • 作者结论认为该常规做法无临床获益,不应继续使用。

核心结论

  • 肾部分切除术中静脉输注甘露醇12.5g与标准化液体水化相比,在术前肾功能正常的患者中无可证实的临床获益,作者认为该做法不应继续。

研究设计与样本

  • 前瞻性、随机、安慰剂对照、双盲试验,纳入199例术前eGFR>45ml/min/1.73m2并计划行肾部分切除术的患者,试验于2012年7月至2015年7月进行。

主要发现

  • 基线中位年龄58岁,中位eGFR为88ml/min/1.73m2。
  • 术后6个月,安慰剂组与甘露醇组调整后eGFR差异为0.2单位,无统计学意义(p=0.9),95%CI为-3.1至3.5,上限排除甘露醇的临床相关效应。

临床怎么用

  • 作者结论认为肾部分切除术中静脉甘露醇12.5g在术前肾功能正常的患者中无临床获益,该做法不应继续(原文结论)。

局限性

  • 局限性包括仅评估了单一甘露醇剂量。
  • 局限性包括所有患者术前肾功能均良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mannitol is currently used as a renal protective agent to mitigate the effects of renal ischemia during nephron-sparing surgery (NSS). This routine practice lacks rigorous methodological study. OBJECTIVE: To assess the effect on renal function outcomes after surgery of mannitol infusion prior to renal ischemia during NSS. DESIGN, SETTING, PARTICIPANTS: This prospective, randomized, placebo-controlled, double-blind trial included 199 patients with a preoperative estimated glomerular filtration rate (eGFR) >45ml/min/1.73m2 scheduled for NSS; the trial was conducted between July 2012 and July 2015. INTERVENTION: Patients undergoing NSS were randomized to receive mannitol (12.5g) or placebo intravenously within 30min prior to renal vascular clamping. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was the difference in eGFR (renal function) between the two groups at 6 mo following surgery assessed with an analysis of covariance model using preoperative eGFR, treatment group, and surgical approach as covariates. RESULTS AND LIMITATIONS: At baseline, the median age of the patients was 58 yr, and the median eGFR was 88ml/min/1.73m2. Comparing placebo with mannitol infusion, the adjusted difference of 0.2 eGFR units at 6 mo was not significant (p=0.9), with the upper bound of the 95% confidence interval (-3.1 to 3.5) excluding a clinically relevant effect of mannitol. Limitations include evaluation of a single mannitol dose and patients all had excellent preoperative renal function. CONCLUSIONS: Intraoperative 12.5g mannitol infusion during NSS has no demonstrable clinical benefit when compared with standardized fluid hydration in patients with normal preoperative renal function, and its use in this setting is not warranted. PATIENT SUMMARY: In this randomized trial, patients with normal kidney function who received mannitol during surgery to remove part of their kidney had no better kidney function 6 mo after surgery than those who did not receive mannitol. We conclude that this routine practice should be discontinued.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Spaliviero M, Power NE, Murray KS, et al. Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. Eur Urol. 2017. PMID: 28822586. doi:10.1016/j.eururo.2017.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。